Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Hepatocellular 36Carcinoma, Non-Small-Cell Lung 17Small Cell Lung Carcinoma 16Neoplasms 14Lung Neoplasms 13Breast Neoplasms 8Melanoma 6Colorectal Neoplasms 6Carcinoma, Renal Cell 6Prostatic Neoplasms 5Liver Neoplasms 5Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Sarcoma 4Neoplasm Metastasis 4Head and Neck Neoplasms 4Glioblastoma 4Endometrial Neoplasms 4Recurrence 3Ovarian Neoplasms 3Neoplasms by Site 3Neoplasms by Histologic Type 3Carcinoma, Transitional Cell 3Uterine Cervical Neoplasms 2Urogenital Neoplasms 2Small Cell Lung Cancer Extensive Stage 2Sarcoma, Alveolar Soft Part 2Osteosarcoma 2Mesothelioma, Malignant 2Mesothelioma 2

Interventions

Cell Count 2atezolizumab 1Immune Checkpoint Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Adenoviridae Infections × atezolizumab × Clear all
NCT07538128 2026-04-20

Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma

Huashan Hospital

Phase EARLY_PHASE1 Recruiting
10 enrolled
CNS

Adenoviridae Infections, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡